Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Merck Serono

Drug Profile

Somatropin - Merck Serono

Alternative Names: r-hGH; Saizen; Serostim; SJ 0011; Zorbtive

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer Bioject; Merck Serono; Savient Pharmaceuticals
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cachexia; Short bowel syndrome; Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Growth disorders; Short bowel syndrome; Short stature; Somatotropin deficiency
  • Phase III Female infertility
  • Discontinued Lipodystrophy

Most Recent Events

  • 08 May 2015 AEterna Zentaris and ASCEND therapeutics agree to promote somatropin in USA
  • 01 May 2015 EMD Serono completes a phase II trial in Female infertility (Adjunctive treatment) in Canada (NCT01204840)
  • 14 Oct 2013 Savient Pharmaceuticals files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top